Post-Hospitalisation COVID-19 Rehabilitation (PHOSP-R): A randomised controlled trial of exercise-based rehabilitation.
Daynes E. et al, (2025), Eur Respir J
Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy.
Tadros R. et al, (2025), Nat Genet
Multiparametric cardiovascular magnetic resonance evaluation of myocardial perfusion, oxygenation, and energetics in hypertrophic cardiomyopathy following cardiac myosin inhibitor therapy.
Finnigan LEM. et al, (2025), Eur Heart J Cardiovasc Imaging, 26
Myocardial disarray and fibrosis across hypertrophic cardiomyopathy stages associate with ECG markers of arrhythmic risk.
Ashkir Z. et al, (2025), Eur Heart J Cardiovasc Imaging, 26, 218 - 228
Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study.
Gharibzadeh S. et al, (2025), EClinicalMedicine, 79
Demographic-Based Personalized Left Ventricular Hypertrophy Thresholds for Hypertrophic Cardiomyopathy Diagnosis.
Shiwani H. et al, (2024), J Am Coll Cardiol
1H and 31P MR Spectroscopy to Assess Muscle Mitochondrial Dysfunction in Long COVID
Finnigan LEM. et al, (2024), Radiology, 313
1H and 31P MR Spectroscopy to Assess Muscle Mitochondrial Dysfunction in Long COVID.
Finnigan LEM. et al, (2024), Radiology, 313
1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study.
Leavy OC. et al, (2024), ERJ Open Res, 10
Association between SARC-F status and long-term physical function after COVID-19 hospitalisation
Mills G. et al, (2024), EUROPEAN RESPIRATORY JOURNAL, 64
Quantitative susceptibility mapping at 7 T in COVID-19: brainstem effects and outcome associations (oct, awae332,2024)
Rua C. et al, (2024), BRAIN, 148, e3 - e3
ABNORMAL SKELETAL METABOLISM BUT NOT CARDIAC DYSFUNCTION AS A CAUSE FOR FATIGUE POST COVID-19
Cassar MP. et al, (2023), JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 81, 1397 - 1397
Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization
Taquet M. et al, (2023), NATURE MEDICINE
Efficacy and Tolerability of AXA1125, an Endogenous Metabolic Modulator Composition, in Fatigue-predominant Long COVID: A Randomized, Double-blind, Placebo-controlled Study
Finnigan L. et al, (2023), AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 207
LIVER DISEASE ACTIVITY IS A SIGNIFICANT RISK FACTOR FOR CARDIOVASCULAR OUTCOMES -A PROSPECTIVE ANALYSIS OF 33,616 INDIVIDUALS FROM THE UK BIOBANK
Roca-Fernandez A. et al, (2023), GASTROENTEROLOGY, 164, S72 - S73
Subclinical Flow Inefficiencies in Non-Obstructive Hypertrophic Cardiomyopathy Subgroups Revealed by 4D Flow Cardiovascular Magnetic Resonance
Pola K. et al, (2023), CIRCULATION, 148
ASSOCIATION OF MRI-DERIVED LIVER BIOMARKERS WITH CARDIOVASCULAR RISK FACTORS, OUTCOMES, AND ALL-CAUSE MORTALITY-A PROSPECTIVE ANALYSIS OF 33,616 INDIVIDUALS FROM THE UK BIOBANK COHORT
Roca-Fernandez A. et al, (2022), HEPATOLOGY, 76, S727 - S728
Cardiopulmonary Assessment of COVID-19 Survivors Stratified by Acute Disease Severity and Post-Acute Symptoms
Szekely Y. et al, (2022), CIRCULATION, 146